Introduction
============

Xenotransplantation, type of medical procedure that could potentially overcome the shortage of human organs for transplantation, relies on the use of domestic pigs as donors of organs and tissues. Xenotransplants could also serve as a temporary solution until an appropriate human donor is found. The possibility of individual transplant selection with regard to size and age represents an additional argument for the use of pigs as donors. Genetically modified pigs are a potential source of cells and tissues for the treatment of Parkinson's disease, diabetes mellitus, and corneal opacity ([@B22]; [@B14]; [@B108]). Currently, intensive research is being carried out on the utility of porcine kidney, heart, lung, and liver tissues for xenotransplantation ([@B14]; [@B82]; [@B108]). Porcine liver tissue could also serve as a source of modified hepatocytes for the treatment of patients with congenital metabolic pathologies in order to rebalance the level of hepatic enzymes. In addition, porcine hepatocytes could be used *ex vivo* in liver perfusion-assist devices ([@B14]). Diabetes mellitus type 1 affects millions of people worldwide, resulting in immense treatment costs. Intensive research is currently focused on the transplantation of encapsulated islets of genetically modified pigs into humans ([@B14]; [@B28]). The application of genetically engineered porcine tissues can also serve as a temporary skin xenograft in the treatment of severe wounds ([@B87]; [@B98]). In ophthalmology, clinical trials utilizing decellularized porcine corneas recellurized by autologous keratocytes are underway ([@B42]; [@B54]). The pigs could also be considered as donors of erythrocytes in transfusiology ([@B14]).

The immunological barriers responsible for transplant rejection, as well as those connected with the risk of the cross-species transmission of PERVs, are being systematically reduced. The introduction of specific mutations involves the elimination of antigens that cause hyper acute rejection (*α1,3-galactosylotransferase* gene knock-out animals) or introduction of genes regulating the functions of the complement system, such as *CD46, CD55*, and *CD59* ([@B30]; [@B66]; [@B93]; [@B115]; [@B46]). Today, there are about 25 known genetic modifications of the porcine genome, with some pigs expressing multiple manipulations ([@B121]; [@B14]). Until recently, genetic modifications relied on the use of synthetic zinc finger nucleases (ZnF) and transcription activator-like effector nucleases (TALEN) ([@B82]). A recent milestone in the field involves the implementation of novel technologies using clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR-Cas9) endonucleases targeting multiple genes in a single reaction ([@B115]; [@B89]). However, genetic engineering of pigs raises new questions. One important concern is the final effect of the multiple editions of porcine genes. How such editing will influence the donor and recipient organisms is yet to be determined.

According to the classification of the International Committee on the Taxonomy of Viruses (ICTV), PERVs belong to the Retroviridae family, Orthoretrovirinae subfamily, Gammaretrovirus genus, and Porcine type-C oncovirus species. They were first described in 1970 as virus-like particles resembling those seen in the baby hamster kidney (BHK-21) cell line and murine cells infected with murine leukemia virus (MLV) ([@B9]). PERVs are closely related to MLV, feline leukemia virus (FeLV), gibbon ape leukemia virus (GaLV), and koala retrovirus (KoRV) ([@B18]). The estimated age of PERVs is about 7.4--8.3 million years ([@B106]; [@B88]; [@B105]). Retroviruses are a virus family with single-stranded RNA (ssRNA) genomes characterized by the presence of reverse transcriptase (RT). This enzyme plays a central role in the replication cycle of retroviruses because it transcribes genomic RNA into double-stranded DNA (dsDNA), called provirus, which is subsequently integrated into the genome of the host cells. Based on the complexity of their genomes, retroviruses can be classified into two groups: those with simple genomes (alpharetroviruses, betaretroviruses, gammaretroviruses, and epsilonretroviruses) and those with complex genomes (lentiviruses, deltaretroviruses, and spumaviruses) ([@B110]). The cells of somatic tissues are the primary targets of retroviral infection by the exogenous retroviruses circulating nowadays. In ancient times, retroviral infections affected the germ line cells, and proviral sequences had the possibility to be passed from one generation to another, becoming endogenous retroviruses (ERVs) ([@B110]; [@B44]). PERVs constitute an integral part of the porcine genome and are present in various proportions depending on pig breed, tissue type, and retrovirus subtype ([@B103]; [@B119]; [@B68]; [@B122]; [@B65]; [@B81]; [@B22]). There are three replication-competent subtypes of PERVs: PERV-A, -B, and -C. PERV-A and -B are polytropic, capable of infecting both porcine and human cells ([@B18]). PERV-C is ecotropic, infecting only porcine cells ([@B104]). However, PERV-A/-C, the result of the recombination of subtypes A and C, is more infectious to human cells than non-recombinant PERV-A ([@B43]). The possibility of infecting human cells (so far only *in vitro*) raises concerns, especially in the context of the eventual use of porcine cells, tissues, and organs in xenotransplantation. Precise knowledge of PERVs' molecular structure and replication cycle is thus necessary for the determination of infection risk and the creation of strategies for PERV detection ([@B19]; [@B4]; [@B38]; [@B55]; [@B37]). This review presents the current knowledge about the structure and replication cycle of PERVs in the context of the retroviral infection risk of human cells.

PERV Molecular Structure
========================

Genomic RNA
-----------

The genomic RNA of PERV is composed of two identical single strands with positive polarity and includes both coding and non-coding sequences. The non-coding sequences are localized at both ends of the RNA, which includes the R and U5 regions at the 5′-end and the U3 and R regions at the 3′-end. Between non-coding sequences, there are sequences encoding the Gag, Pol, and Env proteins, that is, the *gag* (group-specific antigen), *pol* (polymerase gene), and *env* (envelope gene) genes, respectively (**Figure [1A](#F1){ref-type="fig"}**).

![PERV. **(A)** Genomic RNA. **(B)** PERV structure. **(C)** Proviral DNA and nucleotide positions of the main elements. PBS, primer-binding site; SD, splice donor site; ψ, packaging signal psi; SA, splice acceptor site; PPT, polypurine tract; MA, matrix; CA, capsid; NC, nucleocapsid; PR, protease; RT, reverse transcriptase; IN, integrase; SU, surface envelope protein; TM, transmembrane envelope protein; LTR, long terminal repeat; *gag*, group-specific antigen; *pol*, polymerase; *env*, envelope.](fmicb-09-00730-g001){#F1}

The *gag* gene encodes the structural proteins of the matrix (MA), the capsid (CA), and the nucleocapsid (NC) (**Figure [1B](#F1){ref-type="fig"}**). MA is associated with the inner lipid bilayer that descends from a host cell during budding. CA is the main structural protein of PERV, with a molecular weight of about 27 kDa. NC is the third structural protein, with a molecular weight of about 10 kDa (p10), and it is responsible for the efficient packaging of RNA in the virion ([@B2]; [@B17]; [@B27]). In the case of gammaretroviruses, there is one additional protein localized in the Gag polyprotein between MA and CA. This is the p12 protein, which participates in the integration of the dsDNA within the genome of the host cell as well as in the release of new virus particles ([@B74]; [@B94]).

The *pol* gene encodes the following enzymes: protease (PR), RT, and integrase (IN). PR is a protein with a molecular weight of 14 kDa (p14) that catalyzes the proteolysis of the Gag and Pol polyproteins into the proteins described above ([@B16]; [@B7]). RT is responsible for the transcription of viral ssRNA into dsDNA, which is subsequently incorporated into the genome of the host with the help of IN ([@B27]). In contrast to the Pol polyprotein, the products of the *gag* gene can be synthesized alone or as a single large polyprotein together with the products of the *pol* gene. The *gag* stop codon UAG is a part of the PR-coding sequence and can be read through by suppressor tRNA-accepting glutamine ([@B2]; [@B7]).

The *env* gene encodes the proteins of the Env ([@B16]; [@B51]). The Env protein is produced only from spliced *env* mRNA ([@B27]). It is synthesized as a single polyprotein, which is subsequently cleaved by a cellular furin-like PR into two components: the surface envelope protein SU (gp70) and the transmembrane envelope protein TM (p15E) ([@B2]; [@B63]; [@B10]; [@B27]). Env glycoprotein has several glycosylation sites: about 10 in PERV-A, 6 in PERV-B, and 8 in PERV-C. Glycosylation may influence the binding to the host receptor ([@B63], [@B62]). The tropism of the retrovirus depends on the Env proteins. The SU protein is responsible for binding with the host receptor. The receptor-binding domain (RBD) is localized on the N-terminus of the SU protein and contains variable region A (VRA) and variable region B (VRB), localized between amino acids 96 and 126 and between amino acids 163 and 198 of the SU, respectively. The third region that is required for cellular binding is the proline-rich region (PRR), which is localized between amino acids 254 and 298 of the SU protein ([@B109]; [@B36]; [@B18]). The last 100 amino acids of the SU protein are crucial to the binding and infectivity of PERV-C. Moreover, this region differs by only nine residues from the analogous region of PERV-A ([@B36]). It has been demonstrated using the PERV-A/C envelope model that two single amino-acid substitutions can restore chimeric PERV-A/C's ability to infect human cells to a titer equivalent to that of PERV-A. In addition, the tropism of vectors carrying PERV-C envelope mutants with only four amino acid changes in the C-terminus is similar to that of PERV-A ([@B3]). The TM protein is buried in the lipid bilayer and anchors the SU protein to the surface of viral particles. The TM protein mediates the membrane fusion reaction ([@B8]; [@B10]; [@B59]). During the maturation of the virus, the TM protein is cleaved by PR to the p12E protein and R peptide. R peptide cleavage renders the virus capable of fusing with the cells of the host ([@B8]).

The primer-binding site (PBS), the sequence responsible for starting the first RNA strand-reverse transcription (RT), is located between the U5 region and *gag*. In the case of PERV-A and PERV-B, this sequence is complementary with glycine-tRNAs, and for PERV-C, it is complementary with proline-tRNAs. The splice donor (SD) site is situated downstream from the PBS sequence, followed by the packaging signal ψ (psi) ([@B11]). The splice acceptor (SA) site is located between the *pol* and *env* genes. The polypurine tract (PPT) is located between the *env* region and U3. PPT is required for RT as the primer for synthesis of the second strand of the DNA copy ([@B71]; [@B94]). The cap is situated on the 5′-side of the genomic RNA, while the 3′-end contains a polyA tail ([@B2]; [@B16]; [@B71]; [@B111]; [@B94]).

Provirus DNA
------------

Porcine endogenous retrovirus, as an ERV, occurs mainly in the form of provirus integrated within the DNA of the host (pig). The length of the provirus is about 9000 bp ([@B16]; [@B58]; [@B92]; [@B67]; [@B105]). Just like the virus genome, the provirus contains coding sequences *gag, pol*, and *env*. These sequences are flanked by non-coding sequences, called long terminal repeats (LTRs), with U3, R, and U5 regions at both the 5′- and 3′-ends. The length of these LTRs is about 600--800 bp (**Figure [1C](#F1){ref-type="fig"}**; [@B111]; [@B67]). LTRs play an important role in the integration of the provirus within the host genome and the replication cycle of the virus. Moreover, they contain promoter, enhancer, and other regulator sequences important for the subsequent proviral transcription.

U3 appears to be the most heterogeneous region, with many binding sites for numerous transcription factors ([@B96]; [@B26]; [@B111]; [@B40]; [@B90]; [@B50]). In this region, there are direct repeated nucleotide sequences. Due to these repeats, we distinguish two types of LTRs. The first type is characteristic of PERV-A and -B and contains repeated 39 bp sequences. Each repeat consists of one 18 bp and one 21 bp subrepeat sequence ([@B58]; [@B97]; [@B26]; [@B106]; [@B123]). Various types of subrepeat sequences have been observed ([@B47]). The second type of LTR is characteristic of PERV-C and is composed of 37 bp repeats containing 18 bp fragments that are nearly identical to those found in PERV-A. The 37 and 39 bp repeats contain transcription factor-binding sites ([@B97]; [@B26]; [@B111]). A multimerization of these repeats in LTR correlates with an increase in virus titer. In the case of PERV-A/C (containing LTR from PERV-C), the number of 37 bp repeats increases up to the fifth passage on human 293 cells ([@B26]; [@B51]). Three is the optimal number of 39 bp repeats for PERV-A and -B replication ([@B64]). The number of repeats is restricted and balanced by natural instability and the constraints imposed by virion packaging limits ([@B47]). In the replication of such a virus, a lower number of LTR repeats may reflect adaptation to the endogenous replication cycle, with a lower number of transcription factor-binding sites and lower transcriptional activity preventing damage to the host cells ([@B106]). The increase in the number of repeats translates into an increase in the transcriptional activity of the retrovirus as well as an increase of the transcriptional activity of the neighboring host genes after the integration of the provirus ([@B26]). The transcriptional activity of PERVs may also be controlled by DNA methylation and by the inhibition of histone acetylation ([@B48], [@B50]; [@B90]; [@B41]; [@B77]; [@B112]).

The R and U5 regions are conserved sequences with regulatory elements that can affect PERV transcription ([@B97]; [@B111]; [@B49]). The deletion of the R region causes a significant increase in promoter activity ([@B96]).

PERV Replication Cycle
======================

The replication cycle of PERVs is similar to that of other orthoretroviruses, especially gammaretroviruses such as MLV, and can be divided into early and late phases. The early phase includes adsorption onto the cell surface, entry into the cell, RT, and integration within the genome of the host cell (**Figure [2](#F2){ref-type="fig"}**). The late phase includes the expression of retrovirus genes, the release, and maturation of descendant virions.

![Replication cycle of PERV and strategies of PERV detection in xenotransplantation. 1, detection of viral RNA; 2, detection of viral DNA; 3, evaluation of reverse transcriptase activity; 4, detection of PERVs proteins; 5, detection of PERVs antibodies. RT, reverse transcriptase; cross and question mark, PERV-C there is no body of evidence for the possibility of human cells infection *in vivo*.](fmicb-09-00730-g002){#F2}

The Early Phase
---------------

The early phase begins with the binding of PERV SU to the appropriate receptor on the host cell. So far, only receptor for PERV-A has been identified. In pigs, it is porcine PERV-A receptor (PoPAR) ([@B31]). In humans, two PERV-A receptors have been identified: human PERV-A receptor 1 (HuPAR-1) and human PERV-A receptor 2 (HuPAR-2), also known as G-protein-coupled receptors 172A and 172B ([@B80], [@B79]; [@B86]) and as solute carrier family 52 members 2 and 1 (SLC52A2 and SLC52A1), respectively ([@B117]). HuPAR-1 and HuPAR-2 are mammalian riboflavin transporters and are also known as human riboflavin transporter 3 (hRFT3) and human riboflavin transporter 1 (hRFT1), respectively ([@B118]; [@B116]). These receptors are encoded by genes located on chromosomes 8 and 17, respectively, and are widespread in most of the human tissues ([@B31]), although the expression of *huPAR-1* is more ubiquitous ([@B118]; [@B73]; [@B116]). The expression of *huPAR-2* is especially increased in the placenta and the small intestine. In contrast, the expression of *huPAR-1* is particularly enhanced in the brain and salivary glands ([@B116]; [@B86]). HuPAR-1 (445 amino acids) and HuPAR-2 (448 amino acids) are transmembrane proteins that share 86.7% sequence identity. HuPAR-2 is much more functional than HuPAR-1 in terms of PERV-A infection ([@B73]). There are two regions in HuPAR-2's structure that are crucial for PERV-A infection. The first region lies within the first N-terminal 135 amino acids. It contains an absolute determinant of viral envelope binding -- the leucine 109 (L109) as well as seven additional single residues that enhance the efficiency of PERV-A entry without any impact on envelope binding. The second region is located in the middle of HuPAR-2 (a.a. 152--285). This region is responsible for the 11-fold function compared to HuPAR-1 and has no effect on PERV envelope binding ([@B73]). The transcription of *huPAR-2* is controlled by DNA methylation and histone modification ([@B86]). Transcription factor activator protein-2γ (TFAP 2γ) is one of the transcription factors involved in the expression of *huPAR-2* in cytotrophoblast cells ([@B85]).

It was shown that PERV-A, -B, and -C can infect human and rodent cells that lack functional PERV receptors by using transactivation mechanism ([@B60]). The alternative method of infection requires the SU glycoproteins of other gammaretroviruses containing a proline, histidine, glutamine (PHQ) motif or RBD domains and adequate receptors. The PHQ motif is located on the N-terminal region of SU in most gammaretroviruses and is important for virus infectiveness. Histidine is a very important component of this subunit. The mutation or deletion of this amino acid suppresses virus infectiveness and membrane fusion, preserving receptor-binding capability and the incorporation of the Env glycoprotein into the virions. PERVs contain only a portion of the PHQ motif, the tenth histidine (H10). The H10A (histidine↔alanine) mutation suppresses PERV infectivity. However, noninfectious PERVs can be transactivated by adding PHQ-containing SU glycoproteins or soluble RBDs from GaLV. One requirement for this transactivation is a functional GaLV receptor on the cells. Transactivation via GaLV RBD substantially enhances the infectivity of wild-type PERVs, even for cells with PERV receptors. Thus, limited tropism can be overcome with the use of the receptors and domains of other viruses ([@B60]).

The binding of SU with its cell surface receptor induces conformational changes in the gp70 protein as well as its release from the fusion peptide of the TM subunit. As a consequence, the viral Env fuses with the host cell membrane, and the genetic material of the retrovirus covered by the CA enters the cell ([@B59]). In the cytoplasm of the host cell, retroviral RNA is transcribed into dsDNA by retroviral RT within the reverse transcription complex (RTC). The RTC is comprised of genomic RNA, CA, p12 protein, NC, RT, IN, and cellular proteins. CA uncoating occurs after the entry into the host cell and is probably correlated with the RT process ([@B32]). In the case of MLV uncoating happens after nuclear entry following mitosis. After dsDNA synthesis, the RTC changes into the pre-integration complex (PIC), which contains dsDNA as well as proteins from the virus (IN and CA) and the host. Gammaretroviral infection requires dividing cells, when the nuclear membrane has broken down. PIC enters the nucleus and subsequently dsDNA integrates within the host genome forming a stable proviral structure ([@B32]; [@B95]). In the model proposed for MLV, PIC binds to chromosomes during mitosis with the help of p12. After mitosis, PIC is released from chromatin and viral DNA is built into the interphase chromatin with the aid of the IN ([@B95]). The integration of PERV into the human genome (cell line HEK293) is strongly enhanced at sites enriched in CpG islands, especially at transcriptional start sites. These integration sites are flanked by an eight-base palindromic consensus sequence, TG(int)GTACCAGC ([@B83]).

The Late Phase
--------------

Once integrated, the provirus DNA is transcribed by the host machinery to produce descendent retroviruses. The originated mRNA can be used for the production of viral proteins, or become the genomic RNA of new viral particles. The binding of Gag polyproteins to viral genomic RNA occurs in the cytoplasm and is accomplished through the interaction between the NC portion of Gag and a viral RNA ψ sequence. The ψ sequence of PERV has been characterized ([@B11]). Ensuing Gag multimers interact with the cellular membrane, initiating the budding process. Env (SU--TM) glycoproteins then begin to accumulate in the cell membrane ([@B76]; [@B94]). During the docking and release of the nascent virion, [L]{.smallcaps}-domains play a very important role. [L]{.smallcaps}-Domains are short, conserved amino acid motifs in the p12 protein of the Gag polyprotein. The inactivation of this domain leads to the incomplete maturation of the released virions, the reduction of their release, and the accumulation of Gag polyprotein under the cellular membrane ([@B76]). The [L]{.smallcaps}-domain exploits the cellular proteins to enhance the assembly and release of virions. Several proteins are involved in the budding of PERVs, including WW domain-containing protein 2 (WWP2), tumor susceptibility gene 101 (TSG101), and vacuolar protein sorting-associated protein 4 (VPS4) ([@B1]). After the release of the virions from the host cell, PR cleaves Gag polyprotein into minor subunits: MA, CA, and NC. PR also removes the C-terminal residues from the cytoplasmatic tail of the TM protein (R peptide), which is part of the Env protein. In this way, immature PERV particles are converted into mature, infectious virions ([@B8]).

PERV[S]{.smallcaps} and Xenotransplantation Risk
================================================

The ability of PERVs to infect human cells *in vitro* raises concerns, especially in the context of the eventual use of porcine cells, tissues, and organs in xenotransplantation. The possibility of PERV transmission to various human cells, including peripheral blood mononuclear cells (PBMCs) ([@B13]; [@B100]; [@B39]), embryonic kidney cell (HEK-293) line ([@B75]; [@B13]; [@B100]; [@B61]; [@B91]; [@B120]), and normal dermal human fibroblasts (NHDFs) ([@B57]) has been confirmed *in vitro*. However, PERV transmission *in vivo* has not been reported among patients with type 1 diabetes, after pancreatic islets xenografts ([@B45]; [@B35]; [@B107]; [@B78]; [@B84]), recipients of pig's nerve cells ([@B33]), patients with porcine liver cell-based bioartificial liver ([@B29]), porcine skin graft recipients ([@B98]), and butchers exposed to contact with pig tissues ([@B35]; [@B6]). It is possible, that in the case of *in vitro* studies, we are not able to reproduce the complicated dependence networks that have a significant impact on the defense of cells against PERV infection *in vivo*.

Currently, the risk of PERV transmission is considered to be low, assuming that the pigs are adequately and continuously monitored. To minimize the risk of PERV transmission during human xenotransplantation, donor pigs should be selected based on the absence of PERV-C and the lowest expression of PERV-A and -B. Biological materials such as animal saliva or blood should be used for screening. However, if the number of PERV copies in the organ for xenotransplantation differs compared to the material used for screening, an investigation of the whole animal or of its sisters or brothers should be performed ([@B22]). Precise knowledge of the structure and replication cycle of PERVs is a prerequisite for planning strategies for PERV detection ([@B19]; [@B4]; [@B38]; [@B55]; [@B37]). Such detection should be performed at the genomic, transcriptomic, and proteomic levels using methods with adequate sensitivity and specificity. Polymerase chain reaction (PCR), with the use of the primers complementary to the conserved regions of the *gag* and *pol* genes, permits the detection of PERV proviruses in the analyzed biological material. The virus subtype (PERV-A, -B, or -C) can be determined with the primers complementary to *env* gene. Concomitantly the potential risk of recombination between the subtypes can be assessed (PERV-A/C). Primers complementary to the LTRs can serve for the amplification of the whole genome of PERV provirus ([@B70]; [@B103]; [@B53]). RT-PCR, dependent on the analyzed biological material (cells or supernatant), permits the detection of RNA transcribed from the provirus genes or the presence of the viral genome (in particles). Determination of the RT activity further confirms the presence of the virus. Along with the increase of the number of copies of PERV RNA, RT activity can serve as a marker of the active replication cycle. Serology coupled with the use of western blot, ELISA, and immunofluorescence methods complements the diagnostics and can confirm PERV infection (**Figure [2](#F2){ref-type="fig"}**; [@B19]; [@B4]; [@B55]). Visualization by transmission and scanning electron microscopy is also an effective method to confirm the presence of viral particles and their release from infected cells ([@B5]). The genetic material of the virus can also be detected with the use of the *in situ* hybridization technique ([@B113]). This method allows to determine the location of the viral nucleic acid and the percentage of infected cells, giving the opportunity to estimate the viral replication ability and the degree of integration in the host's DNA.

The risk of viral infections due to the use of pigs as donors is estimated to be lower than in the case of human allografts. The use of human donors also carries the risk of transmission of viral infections, such as cytomegalovirus (CMV), viral hepatitis B (HBV), C (HCV), E (HEV), or Epstein--Barr virus (EBV) ([@B114]; [@B25]; [@B20], [@B22]; [@B24]; [@B14]; [@B82]). The urgency of allotransplantation may preclude complex diagnostics in the search for all possible human pathogens. It should also be noted that the immunological barriers of the recipient are substantially depleted by immunosuppression. In the case of xenotransplantation, pigs devoid of pathogens should be bred to ensure the safety of the procedure.

Even a small change in the genetic code of the PERV may be dangerous ([@B36]; [@B3]). Moreover, the barriers associated with the tropism of PERVs to human cells can be overcome with the use of other receptors or their corresponding domains from other viruses or by recombination with other PERV subtypes ([@B43]; [@B60]).

Eventual incorporation of the PERV within the human genome carries the risk that in the case of cell stimulation by other microorganisms, the expression of the virus might change leading to unknown consequences. Lipopolysacharide (LPS) is the most biologically active component of Gram-negative bacteria responsible for the pathophysiological effects associated with infection. *In vitro* studies revealed that LPS can promote virus production or can strongly inhibit virus integration in NHDF cell lines ([@B57], [@B56]).

The characteristic feature of retroviruses---the transcription of genomic RNA into the dsDNA and its incorporation within the host genome---represents a significant threat. It is well known that ERVs are present as a part of the vertebrate genome; however, it is unclear whether they have evolved from an exogenous ancestor or an LTR retrotransposon ([@B44]). ERVs can influence the regulation of expression at genomic and proteomic levels ([@B34]; [@B101]; [@B15]; [@B114]). Expression of the ERVs' Env proteins, called syncytins, plays an important role in the development of the placenta. Envelope proteins provide fusogenic activity for the syncytiotrophoblast formation and regulate its homeostasis ([@B21]). Their immunosuppressive properties contribute to preventing the rejection of the semiallotransplant embryo ([@B21]). ERVs can influence the regulation of the innate immunity ([@B12]), and some may even protect their hosts against viral infection ([@B72]). It has been estimated that about 8% of the human genome consists of retroviral sequences. Potential recombination of one of the three subtypes of PERVs with closely related human ERVs (HERVs), especially HERV-R or HERV-E, cannot be excluded, especially if both elements are located near to one another. Such a situation could theoretically give rise to a new virus with unknown pathogenic potential. Recombination could occur during packaging of PERV and HERV transcripts into a single retroviral particle. Changes in the expression of HERV-W genes have been observed in studies of the human embryonic kidney HEK 293 cell line exposed to PERVs. Both the mRNA and protein abundance of Env were significantly higher than in the control cells ([@B69]). Conversely, studies on infected HEK 293 cells indicated that the recombination potential of PERVs and HERVs was low ([@B102]). Additionally, the evolution gap of about 20 million years between the time of PERV and HERV incorporation into the host genome probably permitted primates to develop adequate defense mechanisms for inactivating foreign ERVs, for example, restriction factors such as apolipoprotein B mRNA editing enzyme catalytic subunit 3 (APOBEC3) ([@B22]). However, the final exclusion of PERV--HERV recombination would necessitate experiments *in vivo* ([@B102]).

The strategies of elimination the potential risks related with PERVs rely on the search of specific vaccines ([@B52]), the use of antiretroviral drugs (mainly azidothymidine AZT) ([@B23]), attempts to reduce the PERVs expression by RNA interference ([@B99]), or inactivation of all PERV proviruses in the pig genome by the CRISPR/Cas technique ([@B115]; [@B89]). With the application of the CRISPR-Cas9 technique, 62 copies of PERV's gene *pol* were deactivated, leading to a 1000 times reduction in the virus ability to infect human cells ([@B115]). Long-term studies are underway to monitor the impact of PERV inactivation and gene editing on PERV-inactivated pigs ([@B89]). However, the question of whether such genetically engineered pigs could serve in the future as a safe resource of tissues and organs for xenotransplantation remains open ([@B22]; [@B108]).

Concluding Remarks
==================

In the near future, the targeted genetic modification of pigs may allow animals to be personalized for the medical needs of specific patients, optimizing treatments and lowering costs. In addition to all the typical safety measures preceding xenotransplantation, clinical trials should be followed by rigorous and lifelong monitoring of the recipient. Better understanding of the PERV replication strategy could contribute to elaborate medical procedures for use in xenotransplantation. Methods should be found preventing the entry of PERVs into cells and blocking the virus at every stage of its replication cycle. Much work is needed before xenotransplantation becomes a safe medical procedure.
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